What is HC Wainwright’s Estimate for MBRX FY2025 Earnings?

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities researchers at HC Wainwright raised their FY2025 earnings estimates for shares of Moleculin Biotech in a report issued on Monday, March 24th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings per share of ($1.65) for the year, up from their previous forecast of ($3.31). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share.

Several other analysts also recently weighed in on the company. Maxim Group raised Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Tuesday. StockNews.com upgraded shares of Moleculin Biotech to a “sell” rating in a research note on Wednesday.

Moleculin Biotech Stock Performance

Shares of NASDAQ:MBRX opened at $1.05 on Thursday. The firm’s 50 day moving average is $1.30 and its two-hundred day moving average is $1.99. Moleculin Biotech has a 52 week low of $0.40 and a 52 week high of $6.23.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.